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Abstract: The aim of this study was to evaluate bone health and body composition by dual-energy
X-ray absorptiometry (DXA) in individuals with Cornelia de Lange Syndrome (CdLS). Overall, nine
individuals with CdLS (five females, all Caucasian, aged 5–38 years) were assessed. Total body
less head (TBLH) and lumbar spine (LS) scans were performed, and bone serum biomarkers were
determined. Molecular analyses were carried out and clinical scores and skeletal features were
assessed. Based on deep sequencing of a custom target gene panel, it was discovered that eight of the
nine CdLS patients had potentially causative genetic variants in NIPBL. Fat and lean mass indices
(FMI and LMI) were 3.4–11.1 and 8.4–17.0 kg/m2, respectively. For TBLH areal bone mineral density
(aBMD), after adjusting for height for age Z-score of children and adolescents, two individuals (an
adolescent and an adult) had low BMD (aBMD Z-scores less than –2.0 SD). Calcium, phosphorus,
25-OH-vitamin D, parathyroid hormone, and alkaline phosphatase levels were 2.08–2.49 nmol/L,
2.10–3.75 nmol/L, 39.94–78.37 nmol/L, 23.4–80.3 pg/mL, and 43–203 IU/L, respectively. Individuals
with CdLS might have normal adiposity and low levels of lean mass measured with DXA. Bone
health in this population seems to be less of a concern during childhood and adolescence. However,
they might be at risk for impaired bone health due to low aBMD in adulthood.
Keywords: Cornelia de Lange syndrome; NIPBL; body composition; bone; dual-energy X-ray absorp-
tiometry
1. Introduction
Brachmann de Lange syndrome and Cornelia de Lange syndrome (CdLS) were first de-
scribed by Brachmann de Lange in 1916 [1] and Cornelia de Lange in 1933, respectively [2].
Advancement in scientific knowledge was rather scarce during the following decades, until
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the 2000s, when research on CdLS grew exponentially [3–6]. Jackson et al. [7] reported
that CdLS was slightly more common in females, but it affects men and women equally.
It has been estimated the prevalence of CdLS is 1 case per 10,000–300,000 live births [3].
Therefore, CdLS is recognized as a rare disease.
CdLS is a consequence of spontaneous mutations in genes of the cohesion protein
complex. NIPBL mutations are the most prevalent variants and occur in approximately
60–80% of cases [8–13]. To date, new advances in genomic techniques are making it possible
for clinicians to improve the diagnosis of mutations in the known CdLS genes (SMC1A,
SMC3, RAD21, BRD4, HDAC8, ANKRD11, and MAU2) [14–19], and other candidates
are being proposed [20]. The CdLS phenotype is characterized as a spectrum because it
includes individuals with the classic CdLS phenotypes (with scores ≥11 points), as well as
individuals with nonclassic CdLS phenotypes (9–10 points), based on the first published
international consensus on the diagnosis and management of CdLS [8].
Recent evidence [8] suggests that most people with CdLS present bone-related medi-
cal problems such as scoliosis or short stature. In addition, cardiovascular problems and
intellectual disability, combined with limited physical activity [3] and restricted mobility,
may harm the bone health and body composition of people with CdLS. However, the
available scientific literature about body composition in these individuals is almost nonex-
istent. We found only two studies [7,21] reporting that 18–30% of adolescents and adults
with CdLS were overweight. Previous studies used body mass index (BMI) to determine
overweight and obesity; however, using the fat mass index (FMI) and lean mass index
(LMI) provides an improvement, because BMI cannot distinguish between fat mass and
lean body mass [22]. As far as we know, when assessing body composition and bone health
in children and adolescents with CdLS, there are no data published with more complex
techniques such as dual-energy X-ray absorptiometry (DXA). However, low bone density
was described in a sample of 12 adults with CdLS [3]. Those authors pointed out that low
bone density could be related to calcium or vitamin D deficiency and/or premature aging.
They also emphasized that the relationship between bone density and fractures should
be further investigated. For that matter, a study by Kline et al. [8] stated that no reliable
studies on osteoporosis in CdLS are available.
Therefore, the primary objective of this study was to evaluate areal bone mineral
density (aBMD) with serum biomarkers in individuals with CdLS. The secondary objective
was to assess body composition in terms of fat and lean mass.
2. Materials and Methods
Participants: A total of 15 individuals with CdLS (10 females, all Caucasian, aged
5–38 years) participated in the present observational study with a case series design. Most
of the individuals were referred by the Spanish Association of Cornelia de Lange Syndrome.
They were evaluated by experienced clinicians in the field of CdLS. Clinicians reviewed
medical records, took standard medical histories, and performed physical examinations to
classify individuals following the international consensus criteria of CdLS [8]. A combina-
tion of cardinal and suggestive features was used to diagnose CdLS phenotypes. Classic
phenotypes are indicated with a score of ≥11 points if at least 3 cardinal features are
identified; a score of 9–10 indicates nonclassic phenotypes if at least 2 cardinal features are
present. In addition, all individuals were subjected to molecular analysis using a custom
targeted gene panel consisting of 35 CdLS-related genes via deep sequencing analysis based
on Ion Chef and Ion S5 XL Systems (Thermo Fisher Scientific), as described previously [23],
including NIPBL, SMC1A, SMC3, RAD21, HDAC8, BRD4, ANKRD11, and MAU2.
Written informed consent was obtained from parents or guardians. The ethical guide-
lines for human research outlined by the Declaration of Helsinki (revision of Fortaleza
2013) [24] and the Declaration of Taipei [25] were followed. The protocol study was ap-
proved by the Ethics Committee of Clinical Research of the Government of Aragón (CEICA;
PI16/225).
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Measurements: Individuals with CdLS underwent anthropometric examination wear-
ing no shoes and minimal clothing. Height was measured to the nearest 0.1 cm with a
stadiometer (SECA 225, SECA, Hamburg, Germany) and weight to the nearest 0.1 kg with
an electronic scale (SECA 861, SECA, Hamburg, Germany). BMI, FMI, and LMI were
calculated as weight (kg) or fat mass (kg) or lean body mass (kg) divided by height squared
(m2). Anthropometric Z-scores were calculated based on Centers for Disease Control
growth charts for children and adolescents age 2 to 20 years. FMI and LMI Z-scores were
calculated based on the body composition reference values published by Hinton et al. [26].
Lumbar spine (LS) and total body less head (TBLH) bone mineral content (BMC) and
aBMD were determined by means of DXA scan, evaluated with the pediatric version of
QDR-Explorer software, version 12.4 (Hologic Corp., Bedford, MA, USA). All scans were
performed by the same operator, who had been fully trained in the operation of the scanner,
the positioning of subjects, and the analysis of scans according to the manufacturer’s
guidelines. Coefficients of variation for the DXA measurements in our laboratory have
already been published [27], and were 2.3% for BMC and 1.3% for aBMD. Adjusted BMC
and aBMD Z-scores, according to the reference values provided by Zemel et al. [28], were
calculated.
Blood samples were collected and centrifuged, and serum was separated into aliquots
in October (autumn). Levels of 25-OH-vitamin D, calcium, phosphorus, alkaline phos-
phatase (ALP), and parathyroid hormone (PTH) were measured by a commercially avail-
able kit using the Roche Cobas 6000 e601 autoanalyzer (Roche Diagnostic, Mannheim,
Germany). Levels of 25-OH-vitamin D and PTH were determined by electrochemilumines-
cence. Levels of calcium, phosphorus, and ALP were measured photometrically.
3. Results
After removing individuals with blurred or incomplete/unfinished DXA scans, 9 in-
dividuals (five females) out of the total sample of 15 individuals with CdLS were finally
analyzed.
3.1. Clinical and Molecular Diagnosis
Based on their clinical scores, six individuals showed classic phenotypes and three
showed nonclassic phenotypes; one had a clinical score of 7 points but a positive molecular
diagnosis. Moreover, eight individuals had likely pathogenic variants in NIPBL, and the
remaining individual had no genetic diagnosis based on NIPBL gene sequencing (Table 1).
3.2. Body Composition and Bone Health
Body composition parameters of the total sample are shown in Table 2. Two of six
children and adolescents were considered to be underweight and one was at risk of over-
weight based on the percentile of BMI for age [29]. Similarly, two of three adults with CdLS
were considered to be underweight and one at risk of overweight by BMI (according to
World Health Organization BMI categories (18.5 to <25, 25 to <30, and ≥30 kg/m2)). We
also used FMI and LMI for a better understanding of body composition assessment of
individuals with CdLS. One adolescent was classified as having high adiposity (≥75th
percentile) [30,31] and three adults were classified as having low adiposity (<25th per-
centile) [31]. Perhaps more importantly, seven out of nine had low levels of lean body mass
(LMI < 25th percentile).
Table 3 shows the bone health parameters. For TBLH, when BMD Z-scores were
adjusted for height for age Z-score of children and adolescents, only two of nine individuals
(an adolescent and an adult) had low BMD (Z-score of −2.0 SD or lower). For LS, only one
adult with CdLS felt into the low BMD category.
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Table 1. Demographic, anthropometric, and clinical characteristics, affected genes, and clinical scores of individuals with Cornelia de Lange syndrome.
Individual I II III IV V VI VII VIII IX
Age (years) 4.7 5.4 14.1 15.1 15.5 17.5 23.5 31.2 37.9
Gender M F M F F M M F F
Tanner stage I I I V V V V V V
Affected gene NIPBL NIPBL NIPBL No genetic variant detected NIPBL NIPBL NIPBL NIPBL NIPBL
Variant type frameshift missense nonsense missense missense exon deletion missense missense
Clinical score 1 13 9 15 11 7 14 13 9 12
Cardinal features
(2 points each if present)
Synophrys and/or thick eyebrows + + + + + + + + +
Short nose, concave nasal ridge, and/or upturned nasal tip + - + - + + + - +
Long and/or smooth philtrum + + + + - + - - -
Thin upper lip vermilion and/or downturned corners of mouth + + + + - + + + +
Hand oligodactyly and/or adactyly - - - - - - - - -
Congenital diaphragmatic hernia - - - - - - - - -
Suggestive features
(1 point each if present)
Global developmental delay and/or intellectual disability + + + + + + + + +
Prenatal growth retardation (<2 SD) 2 + - + - - + + - +
Postnatal growth retardation (<2 SD) 2 + - + + - + + + +
Microcephaly (prenatally and/or postnatally) + - + + - + + + +
Small hands and/or feet + - + + - - + - -
Short fifth finger - + + - + + + + +
Hirsutism - + + + + + + + +
Light gray: children; gray: adolescents; dark gray: adults. 1 According to Kline AD, Moss JF, Selicorni A et al. (2018) Diagnosis and management of Cornelia de Lange syndrome: first international consensus
statement. Nat Rev Genet;19:649–666 [8]. 2 Based on Carrascosa A et al. (2011) Estudios españoles de crecimiento 2010. Rev. Esp. Endocrinol. Pediatr. 2 Suppl (1), 59–62 [32].
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Table 2. Body composition measurements of study sample.
Individual (Gender-Age (Years)) I (M-4.7) II (F-5.4) III (M-14.1) IV (F-15.1) V (F-15.5) VI (M-17.5) VII (M-23.5) VIII (F-31.2) IX (F-37.9)
Height (cm) 93.8 112.1 130.0 148.8 155.3 166.0 157.0 143.2 148.3
Height Z-score –3.1 0.2 –3.9 –2.0 –1.0 –1.3 - - -
Weight (kg) 11.9 19.5 43.1 40.2 55.8 49.8 44.2 36.0 62.8
BMI (kg/m2) 13.5 15.5 25.5 18.2 23.1 18.0 17.9 17.6 28.6
BMI Z-score 1 –2.1 0.3 1.5 –0.7 0.8 –1.6 - - -
BMI percentile 1 2 60 94 24 79 5
FM (kg) 4.1 6.2 18.7 15.2 19.4 9.3 9.9 12.1 23.0
FM (%) 34.1 31.8 43.9 38.2 33.2 19.0 23.6 33.8 37.0
Trunk FM (kg) 1.3 2.0 8.4 6.0 7.7 3.2 4.0 4.6 12.2
Appendicular FM (kg) 2.2 3.5 9.6 8.5 10.8 5.3 5.2 6.7 10.0
Appendicular FMI (kg/m2) 2.5 2.8 5.7 3.9 4.5 1.9 2.1 3.3 4.5
FMI (kg/m2) 4.6 4.9 11.1 6.9 8.1 3.4 4.0 5.9 10.5
FMI classification 2 Normal Normal High Normal Normal Low Low Low Normal
FMI Z-score 3 0.02 † –0.49 † 1.53 –0.15 0.21 –1.20 –1.07 –1.20 0.10
LM (kg) 7.4 12.5 22.8 23.2 36.9 38.0 30.4 22.3 37.2
LM (%) 62.3 64.4 53.3 58.4 63.4 77.1 72.3 62.6 59.9
Trunk LM (kg) 3.3 5.6 11.2 11.7 18.8 19.4 15.6 11.7 20.5
Appendicular LM (kg) 2.4 4.4 9.1 9.1 15.2 15.7 12.2 8.0 13.9
Appendicular LMI (kg/m2) 2.7 3.5 5.4 4.2 6.3 5.7 4.9 3.9 6.4
LMI (kg/m2) 8.4 9.9 13.5 10.6 15.4 13.8 12.3 10.9 17.0
LMI classification 2 Low Low Low Low Normal Low Low Low Normal
LMI Z-score 3 –3.66† –2.06† –1.63 –3.26 0.17 –2.47 –3.76 –3.69 0.41
Light gray: children; gray: adolescents; dark gray: adults. M, male; F, female; BMI, body mass index; FM, fat mass; FMI, fat mass index; LM, lean mass; LMI, lean mass index. Appendicular: sum of four limbs. 1
Relative to age, derived from Centers for Disease Control (CDC) growth data. 2 According to Ofenheimer A et al. (2020). Reference values of body composition parameters and visceral adipose tissue (VAT) by
dual-energy X-ray absorptiometry (DXA) in adults aged 18–81 years—results from the LEAD cohort. European journal of clinical nutrition; 74(8):1181–91 [31]. 3 Based on Hinton J et al. (2017). Dual-energy X-ray
absorptiometry body composition reference values of limbs and trunk from NHANES 1999–2004 with additional visualization methods. PloS ONE 12(3). † Compared with an 8-year-old individual [26].
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Table 3. Bone health parameters of study population.
Individual (Gender-Age (Years)) I (M-4.7) II (F-5.4) III (M-14.1) IV (F-15.1) V (F-15.5) VI (M-17.5) VII (M-23.5) VIII (F-31.2) IX (F-37.9)
DXA
TBLH
Area (cm2) 719.44 834.11 1013.08 1161.89 1507.52 1546.81 1300.78 1197.21 1412.68
BMC (g) 278.31 395.14 701.17 845.45 1465.79 1251.46 1158.35 858.36 1240.15
BMC for age Z-score adjusted for HAZ 1 –0.9 –1.2 –0.4 –1.9 0.73 –2.28 - - -
BMD (g/cm2) 0.387 0.473 0.692 0.727 0.972 0.809 0.890 0.716 0.877
BMD for age Z-score adjusted for HAZ 1 –1.3 –1.2 –0.4 –1.7 1.2 –2.5 - - -
LS (L1-L4)
Area (cm2) 26.15 31.73 33.73 38.84 48.97 56.37 46.77 42.20 50.21
BMC (g) 10.56 14.72 24.22 35.37 56.04 48.61 46.89 32.53 55.09
BMC for age Z-score adjusted for HAZ 1 0.2 –0.2 0.9 –0.5 1.2 –0.6 - - -
BMD (g/cm2) 0.404 0.463 0.718 0.910 1.144 0.862 1.002 0.770 1.097
BMD for age Z-score adjusted for HAZ 1 –0.1 –0.7 1.9 0.7 2.2 –0.5 - - -
Serum Biomarkers
Calcium (nmol/L) 2.47 - 2.46 2.41 2.49 2.34 2.41 2.33 2.08
Phosphorus (nmol/L) 1.65 - 1.16 0.99 1.19 1.06 1.21 0.99 0.68
25-OH-vitamin D (nmol/L) 59.75 - 67.14 78.37 55.66 47.92 71.39 39.94 49.42
PTH (pg/mL) 2 26.1 - 29.7 23.4 29.5 34.9 30.2 37.9 80.3
ALP (IU/L) 2 - - 203 108 129 110 135 43 60
Skeletal features
Restricted mobility No No No No No No No No No
Back pain No No No No Yes No No No No
Scoliosis No No No Yes No No No No No
Vertebral fracture No No No No No No No No No
Other conditions No No Flat feethallux valgus Claw feet No No No No No
Treatments affecting
bone metabolism
Anticonvulsants No No No No LevetiracetamOxcarbazepine No No No No
Proton-pump inhibitors Lansoprazole No Omeprazole No No Omeprazole No No No
Other treatments No No Risperidone No No Risperidone Sertralinehydrochloride Risperidone No No
Light gray: children; gray: adolescents; dark gray: adults. DXA, dual-energy x-ray absorptiometry; TBLH, total body less head; BMC, bone mineral content; BMD, bone mineral density; HAZ, height for
age Z-score; LS, lumbar spine; PTH, parathyroid hormone; ALP, alkaline phosphatase. 1 Based on Zemel B et al. (2011). Revised Reference Curves for Bone Mineral Content and Areal Bone Mineral Density
According to Age and Sex for Black and Non-Black Children: Results of the Bone Mineral Density in Childhood Study. J Clin Endocrinol Metab, 96(10):3160–31. 2 Age-dependent reference values: calcium: 1–5
years: 2.35–2.69 nmol/L; 6–12 years: 2.35–2.57 nmol/L; adults (F) 2.2–2.5 nmol/L, (M) 2.27–2.54 nmol/L; phosphorus: 1–5 years: 1.45–2.10 nmol/L; 6–12 years: 1.16–1.87 nmol/L; 13–20 years: 0.74–1.45 nmol/L;
25-OH-vitamin D: ≥74.87 nmol/L; PTH: 10–65 pg/mL; ALP: children 150–600 IU/L, adults 60–170 IU/L.
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Determination of calcium, phosphorus, 25-OH-vitamin D, PTH, and ALP levels was
not possible for one child with CdLS due to inconvenience in the process of blood collec-
tion. For the remaining group, calcium, phosphorus, 25-OH-vitamin D, PTH, and ALP
levels were 2.08–2.49 nmol/L, 2.10–3.75 nmol/L, 39.94–78.37 nmol/L, 23.4–80.3 pg/mL,
and 43–203 IU/L, respectively. Considering that the normal ranges differ according to
age and sex, only one adult with CdLS had hypocalcemia (calcium 2.08 nmol/L, nor-
mal range 2.2–2.5 nmol/L), hypophosphatemia (phosphorus 0.68 nmol/L, normal range
0.81–1.45 nmol/L), and a low level of ALP (43 IU/L, normal range 60 IU/L). Moreover,
following international guidelines that classify serum concentrations of 25-OH-vitamin D
values above 75 nmol/L as sufficient [33], seven individuals with CdLS were below this cut-
off, and in only one of the oldest individuals the decrease was remarkable (39.94 nmol/L).
Moreover, they also showed the lowest values of calcium, phosphorous, and ALP, ac-
companied by the highest values of PTH. Regarding the skeletal features or treatments
affecting bone metabolism, none of the nine individuals had restricted mobility, used
inhaled glucocorticoids, or took vitamin D supplements.
However, most of the individuals, except one, had gastroesophageal reflux, necessi-
tating the use of proton pump inhibitors for 33.3% of them [3]. In our sample, only one
participant was diagnosed with epilepsy and was using anticonvulsants (levetiracetam
and oxcarbazepine) during the assessments. Nonetheless, this participant did not have
significantly decreased levels of vitamin D (55.66 nmol/L) [34]. One individual was under
treatment with sertraline and two with risperidone due to aggressive behavior. Regarding
possible anomalies of the spine, only one adolescent with CdLS had low-grade scoliosis
without requiring treatment at present, and another reported low back pain in isolation.
Neither vertebral nor other fractures in any individual with CdLS were found, except for a
patient who had suffered a humerus fracture caused by aggressive behavior.
4. Discussion
As far as we know, this is the first study to assess bone health, body composition,
and serum bone biomarkers in a sample of individuals with CdLS. Furthermore, deep
sequencing for a custom target gene panel consisting of 35 genes related to CdLS discovered
causative genetic variants in NIPBL. Therefore, this study will provide useful information
for doctors, researchers, and therapists working with them.
First, our sample consisted of children, adolescents, and adults, which can provide
some information on the different evolutionary stages throughout the lives of people with
CdLS. Although nine individuals may seem like a somewhat small number, our sample is
quite similar to that of a study carried out by Kline et al., in which 14 adults with CdLS were
evaluated by DXA [3]. Moreover, it is important to underline that the assessment of body
composition by DXA in individuals with CdLS is challenging. They must be motionless
for the necessary exploration time. It is also complicated by the intellectual disability they
have and the gastroesophageal reflux that occurs in the supine position.
Previous studies described slow growth of CdLS individuals based on growth
curves [3,35]. On the one hand, some adolescents with CdLS might be underweight;
on the other hand, adolescents with CdLS can became overweight and develop obesity,
which can be induced by high-calorie meals along with low levels of physical activity or
psychotherapeutic treatment options [3].
Along this line, other studies [7,21] reported that between 18 and 30% of adolescents
and adults with CdLS were overweight by BMI. BMI might not be accurate, because it
could be masking important health-related body composition issues. Lean mass in growing
individuals is related to growth as well as size. Thus, performing a more comprehensive
body composition assessment with DXA allowed us to use other indices such as FMI and
LMI. These variables improve on BMI by allowing for an independent assessment of fat
and lean body mass. In addition, the ability to assess FMI and LMI independently and
simultaneously is especially useful for children with chronic diseases [30]. Although seven
out of nine individuals with CdLS had body fat percentages higher than 30%, despite some
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being classified as underweight according to BMI, only one individual was classified as
having high adiposity by BMI. In the remaining sample, five individuals were classified as
having normal adiposity, and three as having low adiposity by FMI. Focusing on lean mass,
seven out of nine individuals were classified as having low levels of lean body mass by LMI.
These findings are especially important in CdLS individuals, because they might show
that fat and lean body mass may be affected differently, and a “normal” BMI may conceal
deficits in lean mass, as happened for participant III (cachectic obesity) [36]. Moreover,
three individuals (VI, VII, and VIII) had low lean body mass and low adiposity, and at
least two of them could be classified as sarcopenic [37,38]. This finding makes it reasonable
to suppose that individuals with CdLS have low levels of lean mass in addition to slow
growth and proportionate small stature [35]. Taking all of these factors into account—low
levels of physical activity, low body weight, and low lean mass—according to Frost’s
mechanostat theory [39], even the youngest individuals with CdLS would be expected to
have low bone mass.
In the present study, using DXA to measure aBMD, we show that two out of nine
individuals had a TBLH aBMD Z-score less than 2.0 SD. Thus, they had low bone min-
eral mass according to the 2019 official Pediatric Positions of the International Society for
Clinical Densitometry (ISCD) [40]. This document indicates that in children with short
stature or growth delay, aBMD results should be adjusted by height Z-scores. In addition,
the diagnosis of osteoporosis in children and adolescents should be made based on den-
sitometry and the presence of a clinically significant fracture history [40]. Interpretations
of our data should be performed with caution, because we did not perform lateral spine
radiographs. Another important consideration is that three out of the nine used or had used
proton pump inhibitors, and there has been emerging evidence showing a link between
long-term proton pump inhibitor usage and bone health [41]. For all the reasons stated
above, analyzing the calcium–PTH–vitamin D axis and ALP levels was imperative.
It was surprising to find that only in the oldest participant the decline in vitamin D
levels was accompanied by a decrease in the level of calcium, which could induce a rise
in PTH level. Future studies are needed to clarify this point. Particularly, there is a need
to carry out other body composition studies in older individuals with CdLS, because in
the above-mentioned situation, bone resorption is expected to increase and could lead to
osteoporosis.
Regarding other treatments affecting bone, seizures are common in CdLS individu-
als, and the use of anticonvulsants may have an impact on bone health and vitamin D
metabolism [3,8,42]. Only one individual (participant V) has epilepsy, currently under
treatment with levetiracetam and oxcarbazepine. Despite that, her bone and vitamin D
values seemed to not be affected. However, it is well known that epilepsy is a prevalent
disorder in childhood and that classic antiepileptic drugs, such as phenobarbital and car-
bamazepine, are inducers of hepatic cytochrome P450 enzymes and can cause vitamin D
deficiency [43–46]. Nonetheless, there are few studies on the effects of newer antiepileptic
drugs like levetiracetam. A recent Spanish study in a pediatric population suggested
there was vitamin D deficiency associated with treatment with the latest generation of
antiepileptic drugs [34]. These discrepancies highlight the importance of accounting for
these factors in future body composition studies.
This study had some limitations. It was a single-center study with a limited sample
size. Moreover, comparisons between groups were not possible due to the lack of a
control group; a normative dataset and Z-score values were used instead. In addition, it is
important to acknowledge that CdLS is a rare disease. Importantly, as far as we know, this
is the first study to document aBMD in some children and adolescents with CdLS.
In conclusion, individuals with CdLS might have normal adiposity by FMI and low
levels of lean mass by LMI measured with DXA. Bone health in this population seems to
not be as much of a concern during childhood and adolescence. However, these individuals
might be at risk for impaired bone health due to low lean mass in adulthood. Accordingly,
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more studies are needed to determine whether there is an increased risk of fracture or poor
musculoskeletal outcomes associated with CdLS.
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